Publications Repository - Helmholtz-Zentrum Dresden-Rossendorf

1 Publication
Theranostic CAR T cell targeting: A brief review
Arndt, C.; Bachmann, M.; Bergmann, R.; Berndt, N.; Feldmann, A.; Koristka, S.;
More than 100 years ago Paul Ehrlich postulated that our immun system should be able to eliminate tumor cells. Just recently, the development of check point inhibitors, bispecific antibodies, and T cells genetically modified to express chimeric antigen receptors (CARs) underlines the true power of our immune system. T cells genetically modified with CARs can lead to complete remission of malignant hematologic diseases. However, they can also cause life-threatening side effects. In case of cytokine release syndrome, tumor lysis syndrome, or deadly side effects on the central nervous system, an emergency shut down of CAR T cells is needed. Targeting of tumor-associated antigens that are also expressed on vital tissues require a possibility to repeatedly switch the activity of CAR T cells on and off on demand and to follow the treatment by imaging. Theranostic, modular CARs such as the UniCAR system may help to overcome these problems.
Keywords: bispecific antibody, BiTE, chimeric antigen receptor, immunotherapy, T cells, UniCAR
  • Journal of Labelled Compounds and Radiopharmaceuticals 62(2019)8, 533-540
    DOI: 10.1002/jlcr.3727

Publ.-Id: 29490 - Permalink